O
Oliver P Guttmann
Researcher at St Bartholomew's Hospital
Publications - 52
Citations - 1956
Oliver P Guttmann is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 16, co-authored 43 publications receiving 1332 citations. Previous affiliations of Oliver P Guttmann include Queen Mary University of London & Barts Health NHS Trust.
Papers
More filters
Journal ArticleDOI
How to develop a more accurate risk prediction model when there are few events
Menelaos Pavlou,Gareth Ambler,Shaun R. Seaman,Oliver P Guttmann,Perry M. Elliott,Michael King,Rumana Z Omar +6 more
TL;DR: Use of penalised regression may improve the accuracy of risk prediction by correcting for the number of predictors in a model.
Journal ArticleDOI
Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review
Oliver P Guttmann,M. Shafiqur Rahman,Constantinos O'Mahony,Aris Anastasakis,Perry M. Elliott +4 more
TL;DR: LA dimension and age are independently associated with AF but the literature is insufficient to create robust clinical tools to predict AF or thromboembolism; most data suggest that AF patients should be anticoagulated.
Journal ArticleDOI
High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction.
Fizzah Choudry,Stephen Hamshere,Krishnaraj S. Rathod,Mohammed M Akhtar,R. Andrew Archbold,Oliver P Guttmann,Simon Woldman,Ajay Jain,Charles Knight,Andreas Baumbach,Anthony Mathur,Daniel A. Jones +11 more
TL;DR: In patients presenting with STEMI and concurrent COVID-19 infection, there is a strong signal toward higher thrombus burden and poorer outcomes, which supports the need for establishing CO VID-19 status in all STEMI cases.
Journal ArticleDOI
International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)
Constantinos O'Mahony,Constantinos O'Mahony,Fatima Jichi,Steve R. Ommen,Imke Christiaans,Eloisa Arbustini,Pablo García-Pavía,Pablo García-Pavía,Franco Cecchi,Iacopo Olivotto,Hiroaki Kitaoka,Israel Gotsman,Gerald Carr-White,Jens Mogensen,Loizos Antoniades,Saidi A Mohiddin,Saidi A Mohiddin,Saidi A Mohiddin,Mathew S. Maurer,Hak Chiaw Tang,Jeffrey B. Geske,Konstantinos C. Siontis,Konstantinos C. Siontis,Karim D. Mahmoud,Karim D. Mahmoud,Alexa M.C. Vermeer,Arthur Wilde,Valentina Favalli,Oliver P Guttmann,Oliver P Guttmann,María Gallego-Delgado,Fernando Domínguez,Ilaria Tanini,Toru Kubo,Andre Keren,Teofila Bueser,Teofila Bueser,Sarah Waters,Issa Farah Issa,James Malcolmson,James Malcolmson,James Malcolmson,Tom Burns,Neha Sekhri,Neha Sekhri,Neha Sekhri,Christopher W. Hoeger,Rumana Z Omar,Perry M. Elliott +48 more
TL;DR: This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.
Journal ArticleDOI
Novel genotype–phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy
Luis R. Lopes,Petros Syrris,Oliver P Guttmann,O'Mahony C,Tang Hc,Chrysoula Dalageorgou,Sharon Jenkins,Mike Hubank,Lorenzo Monserrat,WJ McKenna,Plagnol,Perry M. Elliott +11 more
TL;DR: For the first time, possible influence of variation in non-SP genes associated with other forms of cardiomyopathy and arrhythmia syndromes on the clinical phenotype of HCM is demonstrated.